TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: conflict management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hibiki‐7 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to obtain answers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median HbA(1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with HbA(1c) <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major hypoglycemia occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Time to healing of keratitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rate of keratitis by 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ocular side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Corticosteroid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Virological suppression
Endpoint domain: Mortality/survival
Primary endpoint: Overall general satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean log MRSA CFU count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Low density lipoprotein level (LDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average femoral neck BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average trochanter BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average lumbar spine BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in sports-related injuries
Endpoint domain: Adverse events/effects
Primary endpoint: plasma levels of apoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hot flash incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-leg stance with eyes closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desensitization to an SCD of 4443 mg of WP or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Total Body Fat (%TBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SCMT reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy for detection of the depth of gastric carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of pharmacological and mechanical support
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth weight regain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal power for weight-bearing activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to control of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Need for cardioversion during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for antiarrhythmic therapy at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bioavailability of estradiol and progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patient‐controlled analgesia pump demands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of narcotic delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of plus sign after IVB injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revascularization to the ora serrata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tractional retinal detachment and macular ectopia
Endpoint domain: Adverse events/effects
Primary endpoint: Mobility improvement of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FOLFOX-induced grade 3 or 4 hematologic toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response to LV5FU2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to FOLFOX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total PDS scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: High-sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GRCS (Global Rating of Change Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OAB-q coping and concern
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WPAI-SHP presenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Box and Block test (BBT) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatocellular injury measured by ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient appreciation of audiotaping
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: homeostasis model of assessment‐estimated insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: quantitative insulin sensitivity check index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: severe event
Endpoint domain: Mortality/survival
Primary endpoint: Pain rest relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of 8-iso-prostaglandin F(2alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic cure (grade 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete clinical remission (grade 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with opportunistic screening (Pap smear)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to all-cause treatment discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with facial appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: psychological well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: aging appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal pain
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in body fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative humidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg weight increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time from contact to triaging neurologist to arrival in the regional stroke centre
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessment of OTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination rate for meal-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day rates of major bleeding
Endpoint domain: Mortality/survival
Primary endpoint: 30-day rates of death
Endpoint domain: Mortality/survival
Primary endpoint: 30-day rates of death/myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of IBSQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IBS-severity symptom score (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements on wrinkles of the upper face
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new cognitive deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily living score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in serum oxygen radical-absorbing capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breath ethane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP concentrations and CRC risk association
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IV morphine equivalent consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of diabetes with limited financial resources
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Participant concern
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: stage 3/4 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of blood circulation functional area in the cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vomiting and pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: Perceptions of the exercise program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional performance (TUG and 10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sTNFr1 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spine bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: crush fractures improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first cry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve sustained respiratory pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced-to-oxidized-glutathione ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean surgical field scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cognitive speed improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Short- and long-term memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in systemic level of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion developing diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Rate of reversal to NGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Advanced oxidation protein products (AOPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen radical absorbing capacity (ORAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trolox equivalent antioxidant capacity (TEAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretion of mIL-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alcohol misuse identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain score during the anaesthetic procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to initiation of local numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean change in total BPRS scores at relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in DRI between operative and non-operative management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in new vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time on treadmill
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to Mediterranean diet guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of optimal choices selected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of total fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean venous glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gross mechanical efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutropenic toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in the MSFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in visual acuity/contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrated tympanic membrane temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe postpartum hemorrhage (PPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MMP-1 concentration in carotid plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HDRS scores after six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in abdominal pain (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in C-RP value (inflammation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative pharyngeal complications
Endpoint domain: Adverse events/effects
Primary endpoint: increased proctitis
Endpoint domain: Adverse events/effects
Primary endpoint: increased stool frequency
Endpoint domain: Adverse events/effects
Primary endpoint: poor urinary stream
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of outpatient care for secondary prevention of CHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interpersonal Support Evaluation List (ISEL) scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Endoscopic cure (grade 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure (grade 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial peak plasma leucine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in parent stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in child behavioural issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HDL-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in LDL-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inhibition of wheal and flare responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in Lequesne index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline Folstein mini-mental status examination (MMSE) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of prehospital thrombolytic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of prehospital thrombolytic therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Serum high-sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IGT conversion to diabetes
Endpoint domain: Mortality/survival
Primary endpoint: STAI scoring
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: composite measure of adverse neonatal outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of target lesion revascularization, myocardial infarction, or death
Endpoint domain: Mortality/survival
Primary endpoint: postoperative pulmonary shunt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma epinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of extrasystoles
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients free from IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative hypersensitivities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal adaptation and marginal discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New York Heart Association fraction (NYHA Fc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total frequency amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total savings per patient treated with levosimendan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VAS of tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: panniculitis with arthralgia
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminations for adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Seizure free rate at 12 months
Endpoint domain: Physiological/clinical
Primary endpoint: Initial haemostasis success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: teachers' and parents' ratings of behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lack of dominance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of spontaneous passage of CBD stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first activation of the PCA/NCA pump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children not requiring postoperative morphine
Endpoint domain: Adverse events/effects
Primary endpoint: Morphine consumption during 0-24 h and 24-48 h
Endpoint domain: Adverse events/effects
Primary endpoint: Bacteriuria after biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical signs and symptoms of urinary tract infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hospitalization for febrile UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Appropriateness of TTE utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Hb loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes